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Abstract: Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is a DNA repair enzyme that mends topoisomerase
1-mediated DNA damage. Tdp1 is a current inhibition target for the development of improved anticancer
treatments, as its inhibition may enhance the therapeutic effect of topoisomerase 1 poisons. Here, we report
a study on the development of a novel class of Tdp1 inhibitors that is based on the octahydro-2H-chromene
scaffold. Inhibition and binding assays revealed that these compounds are potent inhibitors of Tdp1,
with IC50 and KD values in the low micromolar concentration range. Molecular modelling predicted
plausible conformations of the active ligands, blocking access to the enzymatic machinery of Tdp1.
Our results thus help establish a structural-activity relationship for octahydro-2H-chromene-based Tdp1
inhibitors, which will be useful for future Tdp1 inhibitor development work.
Keywords: anticancer agent; Tdp1 inhibitor; DNA repair enzyme; synthesis; biochemical assay;
molecular modeling; chemical space; structural-activity relationships
1. Introduction
Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is an enzyme that belongs to the phospholipase D
superfamily [1,2]. Tdp1 functions as a DNA repair enzyme in cells, in which it removes stalled
topoisomerase 1 (Top1)–DNA complexes by catalysing the hydrolysis of phosphodiester bonds between
the tyrosine residue of Top1 and the 3′-phosphate of DNA [3]. Top1 is a current inhibition target
for chemotherapeutic agents [4]. However, Tdp1 also repairs DNA damage that is caused by Top1
inhibitors. Thus, the inhibition of Tdp1 may enhance the efficacy of Top1 poisons, potentially reducing
the side effects of chemotherapeutic treatments and enabling a lower dosage to be used.
Given the potential of Tdp1 inhibition in enhancing the efficacy of anticancer treatments, several
types of Tdp1 inhibitors have been developed [5–14]. Most of these inhibitors show a good to moderate
Molecules 2018, 23, 2468; doi:10.3390/molecules23102468 www.mdpi.com/journal/molecules
Molecules 2018, 23, 2468 2 of 14
inhibition potency, with IC50 values in the concentration range between 0.1 and 20 µM. These include
7-azaindenoisoquinoline derivatives 1 such as triple Top1/Tdp1/Tdp2 inhibitors [5]; achyrodimer F 2,
which is a dimeric cyclobutane metabolite from an Australian fungus of the Cortinariaceae family [6];
7-hydroxycoumarins derivatives 3 that contain aromatic or monoterpene substituents [7]; usnic acid
derivatives, such as 4 with an enamine moiety [8]; compounds that contain the benzopentathiepine
moiety 5 [9]; aminoadamantane-containing monoterpene-derived compound 6 [10]; and furamidine
(NSC 305831), which is a commercial Tdp1 inhibitor [11] (Figure 1), as well as the other less potent
inhibitors of various chemical classes [12–14].
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Figure 1. Structures of reported Tdp1 inhibitors 1–6, commercial Tdp1 inhibitor Furamidine, and octahydro-
2H-chromen-4-ol derivatives 7 that we investigated in this study.
Octahydro-2H-chromene is an oxygen-containing heterocycle with a tetrahydropyran moiety.
This structural scaffold occurs in many important natural products and biologically-active
molecules [15,16]. For example, compounds that contain octahydro-2H-chromen-4-ol were found
to exhibit antiviral and analgesic activities [17,18]. The synthesis of molecules that contain the
octahydro-2H-chromene scaffold has been investigated extensively. In particular, Prins cyclisation
was found to be a flexible method for the synthesis of octahydro-2H-chromenes derivatives. Typically,
the reaction involves a homoallylic alcohol and a carbonyl compound being catalysed by Brønsted
or Lewis acids. The most commonly used catalysts in this transformation are montmorillonite clays
or Lewis acids such as Sc(OTf)3, BF3*Et2O, or I2 [19–22]. Montmorillonite clays were also found to
be effective catalysts for the synthesis of octahydro-2H-chromenes with heterocyclic motifs [23–26].
Although aldehydes containing amino groups cannot be involved in such reactions because of catalyst
poisoning [26], in principle, such products can be obtained through reactions with nitro-aromatic
aldehydes, followed by the reduction of the nitro group. For example, we have successfully obtained
nitro-containing octahydro-2H-chromene from 5-nitro-thiophene-2-carbaldehyde in our previous
work [18]. Moreover, the electron-rich thiophene ring may facilitate the reduction of the nitro group
into an amino group, which is especially important for compounds that are relatively labile, such as
those that contain a tert-hydroxy group. Thus, we reasoned that, due to the versatility and ease of
synthesis, thiophene-2-carbaldehyde is an ideal starting point for the synthesis and derivatisation of
compounds that contain the octahydro-2H-chromene scaffold.
By using a range of octahydro-2H-chromen-4-ol derivatives with different amide motifs 7
(Figure 1), preliminary molecular modelling studies were performed. Our modelling results suggested
that these derivatives may bind to Tdp1. We therefore reasoned that octahydro-2H-chromen-4-ol may
be a useful scaffold for the development of new Tdp1 inhibitors. Herein, we report our work on the
synthesis of a structural series of octahydro-2H-chromen-4-ol derivatives as potential Tdp1 inhibitors.
Inhibition and binding assays were performed to evaluate their inhibition potency and binding affinity
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to Tdp1, respectively. Finally, molecular modelling was performed to predict the plausible binding
conformations of these compounds.
2. Results and Discussion
2.1. Synthesis of Octahydro-2H-chromen-4-ol Derivatives
Nitro compounds 8 with an octahydro-2H-chromen-4-ol scaffold were synthesised as a mixture of
diastereomers on the C-4 position in a reaction of (-)-isopulegol with 5-nitrothiophene-2-carbaldehyde
in the presence of montmorillonite K10 clay (Scheme 1).
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2.2. Tdp1 Inhibition and Binding Assays
The inhibition pote cy of our synthesised compounds against Tdp1 was evaluated by using a
real-time oligonucleotide biosensor-based assay [27]. In this assay, Tdp1 catalyses the removal of
fluorophore quenchers from the 3′-end of a modified DNA substrate [27]. Fluorescence intensity
hence reflects the catalytic activity of the enzyme. Hexadecameric oligonucleotide was selected as a
Tdp1 substrate, as it contains 5(6)-carboxyfluorescein (FAM) at the 5′-end and fluorophore quencher
BHQ1 (Black Hole Quencher-1) at the 3′-end [9]. This approach was used to determine the inhibitory
properties of all the chromenes.
All our synthesised compounds except derivatives 8 and 9 were found to exhibit inhibitory
activity against Tdp1 in the low micromolar range (Table 1). Compounds with IC50 > 15 µM were
considered inactive. The (4S)-diastereomer with the most bulky substituent was found to be the most
potent (13), with an IC50 value of 1.24 µM. In general, the IC50 values for the (4S) series are in the IC50
of 1.24 to 5.8 µM range. For (4R)-diastereomers, their IC50 values were found to be similar.
Table 1. Inhibitory Potency (IC50) and Binding Affinity (KD) of Compounds 8–13 Against Tdp1.
Compound IC50, µM KD, µM
R (4S) (4R) (4S) (4R)
8
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for GoldScore and ChemPLP. The correlation between the measured affinities and the predicted 
binding values is reassuring, particularly since ChemPLP is considered to be the most robust function 
used [30] and strengthens the overall applicability of the modelling. 
The docked configurati n of the most active derivativ ( S)-13 is shown in Figure 2. Our docking 
model evealed that the ligand is in lipophili  contact (LC) with His263, Tyr204, Ala520, Ala521, and 
Pro461, and exhibited hydrogen bonding with Gly458 and Ser459 via the hydroxyl group. Also, the 
hydrophobic pocket in the binding site is occupied by the adamantane moiety and the thiophene 
group occupies a cleft exposed to the water nvironment, as sh wn in Figure 2A. Derivative (4S)-11, 
which shows a similar inhibition potency to (4S)-13, is predicted to have LC with His263 and Tyr204 
in a similar manner to (4S)-13. However, (4S)-11 displayed a hydrogen bonding interaction with 
His493 through its hydroxyl group, unlike (4S)-13. This suggests that the different substituents on 
the amide group can have an important effect in o ienting the ligands in the binding site of the 
enzyme. It is established that for Td 1, both His263 and His493 play a key role in its biological 
fun tion and the bin in  pocket was defined there [1,7,9]. It can therefore be stated that a plausible 
binding mode is predicted as the ligands block access to these key amino acid residues. 
The calculated molecular descriptors (MW-molecular weight, log P octanol–water partition 
coefficient, HD–hydrogen bond donors, HA-hydrogen bond acceptors, PSA–polar surface area, and 
RB–rotatable bonds) for the six isomers (4S, 4R) are given in Table S1 (see Supplementary Material). 
The ligands are relatively average in size, with a molecular weight between 281.4 and 443.6.8 (4R, 
4S), and nine (4R, 4S) derivatives lie in the lead-like space, while others are within the boundaries of 
the drug-like space (for definition of lead-like, drug-like, and Known Drug Space regions, see ref 
[31]). The log P values range from 2.3 to 5.1, with only compounds (4R, 4S)-8, (4R, 4S)-9, and (4R)-10 
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In addition to the inhibition assay, the binding of our compounds to Tdp1 was also evaluated.
An intrinsic protein fluorescence-based assay, which we have previously applied to study the binding
of esters combining monoterpenoid and adamantane fragments, was applied [28]. In agreement
with the inhibition data, all our compounds were relatively strong binders to Tdp1, with dissociation
constants (KD) in the low µM region (Table 1 and Supplementary Figures S1–S7). Interestingly, all our
compounds appeared to bind Tdp1 to more than one binding pocket (i.e., specific and non-specific
binding). This is possibly due to the large hydrophobic surface of Tdp1. The slight discrepancy
between the measured KD and IC50 values is likely due to these non-specific binding events.
2.3. Molecular Modelling
Both isomers (4R, 4S) of the six ligands were docked into Tdp1 (PDB ID: 1MU7) [2,29] using GOLD
and all the ligands fitted into the pocket in a similar way with a reasonable predicted affinity for the
scoring functions used, as can be seen in Table 2. GoldScore (GS) and, in particular, Chem Piecewise
Linear Potential (ChemPLP), scoring functions give higher scores for 10–13 (4R, 4S) compared to
(4R, 4S)-8 and (4R, 4S)-9, which is consistent with their IC50 values. A similar trend is also observed
for ChemScore (CS) and Astex Statistical Potential (ASP), albeit not as pronounced as for GoldScore
and ChemPLP. The correlation between the measured affinities and the predicted binding values is
reassuring, particularly since ChemPLP is considered to be the most robust function used [30] and
strengthens the overall applicability of the modelling.
The docked configuration of the most active derivative (4S)-13 is shown in Figure 2. Our docking
model revealed that the ligand is in lipophilic contact (LC) with His263, Tyr204, Ala520, Ala521,
and Pro461, and exhibited hydrogen bonding with Gly458 and Ser459 via the hydroxyl group.
Also, the hydrophobic pocket in the binding site is occupied by the adamantane moiety and the
thiophene group occupies a cleft exposed to the water environment, as shown in Figure 2A. Derivative
(4S)-11, which shows a similar inhibition potency to (4S)-13, is predicted to have LC with His263 and
Tyr204 in a similar manner to (4S)-13. However, (4S)-11 displayed a hydrogen bonding interaction
with His493 through its hydroxyl group, unlike (4S)-13. This suggests that the different substituents on
the amide group can have an important effect in orienting the ligands in the binding site of the enzyme.
It is established that for Tdp1, both His263 and His493 play a key role in its biological function and the
binding pocket was defined there [1,7,9]. It can therefore be stated that a plausible binding mode is
predicted as the ligands block access to these key amino acid residues.
The calculated molecular descriptors (MW-molecular weight, log P octanol–water partition
coefficient, HD–hydrogen bond donors, HA-hydrogen bond acceptors, PSA–polar surface area,
and RB–rotatable bonds) for the six isomers (4S, 4R) are given in Table S1 (see Supplementary Material).
The ligands are relatively average in size, with a molecular weight between 281.4 and 443.6.8 (4R, 4S),
and nine (4R, 4S) derivatives lie in the lead-like space, while others are within the boundaries of the
drug-like space (for definition of lead-like, drug-like, and Known Drug Space regions, see ref [31]).
The log P values range from 2.3 to 5.1, with only compounds (4R, 4S)-8, (4R, 4S)-9, and (4R)-10 being
slightly outside of the ideal drug-like space but within the Known Drug Space. Moreover, the Polar
Surface Area (PSA) values also indicate that they lie in the drug-like space.
The SAR and modelling studies clearly indicate that lipophilic R-groups are potentially
beneficial for improved binding of this class of compounds to Tdp1. To investigate this possibility,
four derivatives with the R-groups α-naphthyl (14), β-naphthyl (15), isopropyl (16), and tert-butyl (17)
were docked into the binding site and their scores are given in Table 2. Compared with the scores for the
most active compounds 11 and 13, it can be seen from Table 2 that the α-naphthyl substitution gives
favourable scores for both GS and ChemPLP, suggesting that this derivative may be a promising
derivative to synthesise and test. The other substitutions gave similar or worse scores compared to
11 and 13. Similar binding poses were predicted for derivatives 14–17 as for their 8–13 counterparts.
Finally, derivatives 14 and 15 have slightly higher Log P values than 13, but have essentially the same
values for the other molecular descriptors (see Table S1 in the SI).
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Table 2. Results of the Scoring Functions (GS, CS, ChemPLP, and ASP) for Compounds 8–17 with Tdp1.
The IC50 Values of Compounds 8–13 with Tdp1 were Also Included.
Compound GS CS ChemPLP ASP IC50 (µM)
(4R)-8 40.1 26.0 47.9 27.4 >15
(4S)-8 41.0 25.3 45.0 26.6 >15
(4R)-9 41.5 25.0 41.1 27.2 >15
(4S)-9 42.2 25.5 45.5 29.0 >15
(4R)-10 42.3 25.9 50.7 28.9 2.9 ± 0.8
(4S)-10 44.0 25.2 49.4 28.4 5.8 ± 3.0
(4R)-11 39.6 23.8 51.8 34.4 4.0 ± 0.4
(4S)-11 44.0 25.2 50.6 31.3 1.4 ± 0.3
(4R)-12 55.8 30.3 57.2 29.1 3.3 ± 0.2
(4S)-12 56.0 30.8 56.4 29.8 5.0 ± 1.5
(4R)-13 51.5 32.3 57.1 30.5 2.8 ± 0.6
(4S)-13 52.5 31.4 56.1 30.4 1.24 ± 0.02
(4R)-14 60.9 30.9 60.4 31.3 -
(4S)-14 62.5 29.6 61.3 32.8 -
(4R)-15 50.2 30.5 64.8 32.6 -
(4S)-15 53.6 28.2 59.6 28.5 -
(4R)-16 48.7 23.2 51.6 25.9 -
(4S)-16 48.8 21.5 48.5 27.5 -
(4R)-17 49.2 21.9 49.3 25.1 -
(4S)-17 51.2 22.2 47.9 27.7 -
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Ala520, Ala521, and Pro461. 
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Agilent 5975C as a detector. A 30-m quartz column HP-5MS (copolymer 5%–diphenyl–95%–
dimethylsiloxane) with an inner diameter of 0.25 mm and the stationary phase film thickness of 0.25 
μm was used. Optical rotation parameters: polAAr 3005 spectrometer; CHCl3 soln. 1H and 13C NMR: 
Bruker DRX-500 apparatus at 500.13 MHz (1H) and 125.76 MHz (13C), J in Hz; structure was 
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2D homonuclear correlation, J-modulated 13C NMR spectra (JMOD), and 13C –1H 2D heteronuclear 
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Hz, COLOC, 2,3J(C,H) = 10 Hz). HR-MS: DFS Thermo Scientific spectrometer in a full scan mode (15-
500 m/z, 70 eV electron impact ionisation, direct sample administration). 
All product yields are given as pure compounds obtained from the column chromatography. 
Column chromatography: silica gel (SiO2; 60-200 μ; Macherey-Nagel); hexane, solution containing 
from 0 to 100% EtOAc in hexane, ethanol. The purity of the target compounds was determined by 
GC-MS methods. The purity of all target compounds reported in this paper exceeds 95%. 
Please note that the numeration of the atoms of products is performed as shown in Figure 3. 
Figure 2. Docked configurations of derivative (4S)-13 to the substrate binding sites predicted by
the Ch mPLP algorithm. The protein surface is rendered where p rtial positive, negative charges,
and neutral regions are colored blue, red, and grey, spectively (A). The hydrogen bond interactions
ar depicted as g en lin s etwe n compound (4S)-13 and the amino acids residues; Ser459 and
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3. Materials and Methods
3.1. Chemistry
3.1.1. General Materials and Methods
Chemicals were purchased from commercial sources (Sigma-Aldrich, St. Louis, MO, USA; Acros,
Morris Plains, NJ, USA) and used with no further treatment. The K10 clay (Aldrich) was used as the
catalyst of the reaction. The clay was dried at 105 ◦C for 3 h prior to use. Dichloromethane CH2Cl2
was dried with calcined Al2O3. For the products structure analysis, GC-MS was used, consisting of an
Agilent 7890A gas chromatograph equipped with a quadrupole mass spectrometer Agilent 5975C as a
detector. A 30-m quartz column HP-5MS (copolymer 5%–diphenyl–95%–dimethylsiloxane) with an
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inner diameter of 0.25 mm and the stationary phase film thickness of 0.25 µm was used. Optical rotation
parameters: polAAr 3005 spectrometer; CHCl3 soln. 1H and 13C NMR: Bruker DRX-500 apparatus
at 500.13 MHz (1H) and 125.76 MHz (13C), J in Hz; structure was determined by analysing the
1H NMR spectra, including 1H–1H double resonance spectra and 1H–1H 2D homonuclear correlation,
J-modulated 13C NMR spectra (JMOD), and 13C –1H 2D heteronuclear correlation with one-bond and
long-range spin-spin coupling constants (C–H COSY, 1J(C,H) = 160 Hz, COLOC, 2,3J(C,H) = 10 Hz).
HR-MS: DFS Thermo Scientific spectrometer in a full scan mode (15-500 m/z, 70 eV electron impact
ionisation, direct sample administration).
All product yields are given as pure compounds obtained from the column chromatography.
Column chromatography: silica gel (SiO2; 60-200 µ; Macherey-Nagel); hexane, solution containing
from 0 to 100% EtOAc in hexane, ethanol. The purity of the target compounds was determined by
GC-MS methods. The purity of all target compounds reported in this paper exceeds 95%.
Please note that the numeration of the atoms of products is performed as shown in Figure 3.Molecules 2018, 23, x FOR PEER REVIEW  8 of 14 
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3.1.2. Chemical Syntheses
The syntheses and characterisations of (2R,4aR,7R,8aS)-4,7-Dimethyl-2-(5-nitrothiophen-2-
yl)octahydro-2H-chromen-4-ols, (4S)-8, and (4R)-8, were reported previously [18].
(2R,4R,4aR,7R,8aS)-4,7-Dimethyl-2-(5-aminothiophen-2-yl)octahydro-2H-chromen-4-ol, (4R)-9. To the
solution of nitro compound (4R)-8 (0.436 g) in EtOH (20 mL), Na2S2O4 (2.300 g) and K2CO3 (1.900 g)
in water (10 mL) were added, and the mixture was stirred at r.t. for 2 h. After the completion of the
reaction, 10 L of a saturated aq. NaCl solution was added to the reaction mixture and extracted
with ethyl acetate (3 × 10 mL). The organic layer was washed with brine (2 × 10 mL) and dried over
anhydrous sodium sulphate. The organic layer was concentrated in a rotary evaporator and separated
using an SiO2 column. Purification resulted in the yield of (4R)-9 (0.234 g, 60%). 1H-NMR (CDCl3)
(ppm) δ: 0.88–0.97 (m, 1H, Ha-8); 0.92 (d, J(16, 9a) = 6.5 Hz, 3H, H-16); 1.05 (ddd, J(10a, 10e) = J(10a, 9a)
= 12.1 Hz, J(10a, 1a) = 11.2 Hz, 1H, Ha-10); 1.09–1.20 (m, 2H, Ha-6, Ha-7); 1.24 (s, 3H, H-15); 1.41–1.52
(m, 1H, Ha-9); 1.67 (dd, J(4a, 4e) = 13.4 z, J(4a, 3a) = 11.6 Hz, 1H, Ha-4); 1.72 (dm, J(8e, 8a) = 13.1 Hz,
other J < 3.5 Hz, 1H, He-8); 1.77–1.83 (m, 1H, He-7); 1.95 (dd, J(4e, 4a) = 13.4 Hz, J(4e, 3a) = 2.4 Hz, 1H,
He-4); 1.97 (dm, J(10e, 10a) = 12.1 Hz, other J < 4.5 Hz, 1H, e-10); 3.21 (ddd, J(1a, 10a) = 11.2 z, J(1a,
6a) = 9.7 z, J(1a,10e) = 4.2 Hz, 1H, Ha-1); 4.49 (ddd, J(3a, 4a) = 11.6 Hz, J(3a, 4e) = 2.4 Hz, J(3a, 14) =
1.0 Hz, 1H, a-3); 5.99 (d, J(14, 13) = 3.5 Hz, 1H, -14); 6.53 (d, J(13, 14) = 3.5 Hz, 1H, H-13). 13C-NMR
(CDCl3) (ppm) δ: 72.13 (d, C-1); 70.63 (d, C-3); 47.25 (t, C-4); 69.99 (s, C-5); 49.22 (d, C-6); 22.28 (t, C-7);
34.14 (t, C-8); 31.08 (d, C-9); 40.83 (t, C-10); 150.56 (s, C-11); 132.81 (s, C-12); 122.36 (d, C-13); 107.64 (d,
C-14); 27.92 (q, C-15); 22.01 (q, C-16). HR MS: 281.1449 (M+, 15H23O2NS+; calc. 281.1444). [α]
26.0
D =
+7.2 (c 0.334, EtOH).
(2R,4S,4aR,7R,8aS)-4,7-dimethyl-2-(5-aminothiophen-2-yl)octahydro-2H-chromen-4-ol, (4S)-9. To the
solution of nitro compound (4S)-8 (0.223 g) in EtOH (20 mL), Na2S2O4 (1.300 g) and K2CO3 (1.000 g)
solution in water (10 mL) was added, and the mixture was stirred at r.t. for 2 h. After the completion of
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the reaction, 10 mL of a saturated aq. NaCl solution was added to the reaction mixture and extracted
with ethyl acetate (3 × 10 mL). The organic layer was washed with brine (2 × 10 mL) and dried over
anhydrous sodium sulphate. The organic layer was concentrated in a rotary evaporator and separated
on an SiO2 column. Purification resulted in the yield of (4S)-9 (0.167 g, 80%). 1H-NMR (CDCl3) (ppm)
δ: 0.88–0.97 (m, 1H, Ha-8); 0.93 (d, J(16, 9a) = 6.5 Hz, 3H, H-16); 1.04 (ddd, J(10a, 10e) = J(10a, 9a) =
12.1 Hz, J(10a, 1a) = 11.2 Hz, 1H, Ha-10); 1.10–1.21 (m, 2H, Ha-6, Ha-7); 1.24 (s, 3H, H-15); 1.41–1.53
(m, 1H, Ha-9); 1.67 (dd, J(4a, 4e) = 13.4 Hz, J(4a, 3a) = 11.6 Hz, 1H, Ha-4); 1.72 (dm, J(8e, 8a) = 13.1 Hz,
other J < 3.5 Hz, 1H, He-8); 1.77–1.83 (m, 1H, He-7); 1.94 (dd, J(4e, 4a) = 13.4 Hz, J(4e, 3a) = 2.4 Hz, 1H,
He-4); 1.97 (dm, J(10e, 10a) = 12.1 Hz, other J < 4.5 Hz, 1H, He-10); 3.52 (ddd, J(1a, 10a) = 11.2 Hz, J(1a,
6a) = 9.7 Hz, J(1a,10e) = 4.2 Hz, 1H, Ha-1); 4.82 (ddd, J(3a, 4a) = 11.6 Hz, J(3a, 4e) = 2.4 Hz, J(3a, 14) =
1.0 Hz, 1H, Ha-3); 5.98 (d, J(14, 13) = 3.6 Hz, 1H, H-14); 6.51 (d, J(13, 14) = 3.6 Hz, 1H, H-13). 13C-NMR
(CDCl3) δ: 76.89 (d, C-1); 72.73 (d, C-3); 47.54 (t, C-4); 69.98 (s, C-5); 49.12 (d, C-6); 22.28 (t, C-7); 34.14
(t, C-8); 31.08 (d, C-9); 40.83 (t, C-10); 150.22 (s, C-11); 131.81 (s, C-12); 120.26 (d, C-13); 108.60 (d, C-14);
27.91 (q, C-15); 22.00 (q, C-16). HR MS: 281.1449 (M+, C15H23O2NS+; calc. 281.1444). [α]
29.1
D = −6.25
(c 0.16, EtOH).
General Procedure for the Preparation of Compounds 10–11. To the solution of amine 9 (1.0 mmol)
in EtOAc, acid anhydride solution (1.0 mmol) in the presence of 4-DMAP (0.01 mmol) was added
dropwise, and the mixture was stirred at r.t. for 2 h. After the completion of the reaction, 10 mL
of a saturated aq. NaHCO3 solution was added to the reaction mixture and extracted with ethyl
acetate (3 × 10 mL). The organic layer was washed with brine (2 × 10 mL) and dried over anhydrous
sodium sulphate. The organic layer was concentrated in a rotary evaporator and separated using an
SiO2 column.
N-(5-((2R,4R,4aR,7R,8aR)-4-Hydroxy-4,7-dimethyloctahydro-2H-chromen-2-yl)thiophen-2-yl)acetamide,
(4R)-10. The reaction of amine (4R)-9 (0.100 g) and acetic anhydride (0.037 g) in the presence of
4-DMAP (0.001 g) for 2 h resulted in the yield of (4R)-10 (0.031 g, 35%). 1H-NMR (CDCl3) (ppm) δ:
0.80–0.88 (m, 1H, Ha-8); 0.82 (d, J(16, 9a) = 6.5 Hz, 3H, H-16); 0.94 (ddd, J(10a, 10e) = J(10a, 9a) =
12.1 Hz, J(10a, 1a) = 11.2 Hz, 1H, Ha-10); 1.03–1.12 (m, 2H, Ha-6, Ha-7); 1.14 (s, 3H, H-15); 1.33–1.43
(m, 1H, Ha-9); 1.63 (dd, J(4a, 4e) = 13.4 Hz, J(4a, 3a) = 11.6 Hz, 1H, Ha-4); 1.70–1.89 (m, 4H, He-7, He-8,
He-4, He-10); 2.03 (s, 3H, H-18); 3.18 (ddd, J(1a, 10a) = 11.2 Hz, J(1a, 6a) = 9.7 Hz, J(1a, 10e) = 4.2 Hz,
1H, Ha-1); 4.51 (ddd, J(3a, 4a) = 11.6 Hz, J(3a, 4e) = 2.4 Hz, J(3a, 14) = 1.0 Hz, 1H, Ha-3); 6.39 (d, J(14,
13) = 3.8 Hz, 1H, H-14); 6.62 (d, J(13, 14) = 3.8 Hz, 1H, H-13). 13C-NMR (CDCl3) (ppm) δ: 77.51 (d, C-1);
72.51 (d, C-3); 49.32 (t, C-4); 70.26 (s, C-5); 51.50 (d, C-6); 22.83 (t, C-7); 34.16 (t, C-8); 31.28 (d, C-9);
41.09 (t, C-10); 136.11 (s, C-11); 138.77 (s, C-12); 110.66 (d, C-13); 120.60 (d, C-14); 22.37 (q, C-15); 20.60
(q, C-16); 167.39 (s, C-17); 21.95 (q, C-18). HR MS: 323.1547 (M+, C17H25NO3S+; calc. 323.1550). [α]
28.0
D
= +7.48 (c 0.107, EtOH).
N-(5-((2R,4S,4aR,7R,8aR)-4-Hydroxy-4,7-dimethyloctahydro-2H-chromen-2-yl)thiophen-2-yl)acetamide, (4S)-
10. The reaction of amine (4S)-9 (0.040 g) and acetic anhydride (0.015 g) in the presence of 4-DMAP
(0.001 g) for 2 h resulted in the yield of (4S)-10 (0.043 g, 95%). 1H-NMR (CDCl3) (ppm) δ: 0.80–0.88
(m, 1H, Ha-8); 0.82 (d, J(16, 9a) = 6.5 Hz, 3H, H-16); 0.94 (ddd, J(10a, 10e) = J(10a, 9a) = 12.1 Hz, J(10a,
1a) = 11.2 Hz, 1H, Ha-10); 1.03–1.12 (m, 2H, Ha-6, Ha-7); 1.14 (s, 3H, H-15); 1.33–1.43 (m, 1H, Ha-9);
1.63 (dd, J(4a, 4e) = 13.4 Hz, J(4a, 3a) = 11.6 Hz, 1H, Ha-4); 1.70–1.89 (m, 4H, He-7, He-8, He-4, He-10);
2.01 (s, 3H, H-18); 3.50 (ddd, J(1a, 10a) = 11.2 Hz, J(1a, 6a) = 9.7 Hz, J(1a, 10e) = 4.2 Hz, 1H, Ha-1); 4.85
(ddd, J(3a, 4a) = 11.6 Hz, J(3a, 4e) = 2.4 Hz, J(3a, 14) = 1.0 Hz, 1H, Ha-3); 6.37 (d, J(14, 13) = 3.8 Hz, 1H,
H-14); 6.59 (d, J(13, 14) = 3.8 Hz, 1H, H-13). 13C-NMR (CDCl3) (ppm) δ: 75.77 (d, C-1); 70.71 (d, C-3);
47.34 (t, C-4); 68.95 (s, C-5); 49.31 (d, C-6); 22.40 (t, C-7); 34.32 (t, C-8); 31.17 (d, C-9); 40.97 (t, C-10);
136.94 (s, C-11); 138.64 (s, C-12); 110.89 (d, C-13); 120.92 (d, C-14); 22.41 (q, C-15); 20.81 (q, C-16);
167.39 (s, C-17); 22.03 (q, C-18). HR MS: 323.1547 (M+, C17H25NO3S+; calc. 323.1550). [α]
27.8
D = +20.5
(c 0.16, EtOH).
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2,2,2-Trifluoro-N-(5-((2R,4R,4aR,7R,8aR)-4-hydroxy-4,7-dimethyloctahydro-2H-chromen-2-yl)thiophen-2-
yl)acetamide, (4R)-11. The reaction of amine (4R)-9 (0.110 g) and trifluoroacetic anhydride (0.082 g)
in the presence of 4-DMAP (0.001 g) for 2 h resulted in the yield of (4R)-11 (0.043 g, 30%). 1H-NMR
(CDCl3) (ppm) δ: 0.80-0.88 (m, 1H, Ha-8); 0.82 (d, J(16, 9a) = 6.5 Hz, 3H, H-16); 0.94 (ddd, J(10a, 10e) =
J(10a, 9a) = 12.1 Hz, J(10a, 1a) = 11.2 Hz, 1H, Ha-10); 1.03–1.12 (m, 2H, Ha-6, Ha-7); 1.14 (s, 3H, H-15);
1.33–1.43 (m, 1H, Ha-9); 1.63 (dd, J(4a, 4e) = 13.4 Hz, J(4a, 3a) = 11.6 Hz, 1H, Ha-4); 1.70–1.89 (m, 4H,
He-7, He-8, He-4, He-10); 3.16 (ddd, J(1a, 10a) = 11.2 Hz, J(1a, 6a) = 9.7 Hz, J(1a, 10e) = 4.2 Hz, 1H,
Ha-1); 4.50 (ddd, J(3a, 4a) = 11.6 Hz, J(3a, 4e) = 2.4 Hz, J(3a, 14) = 1.0 Hz, 1H, Ha-3); 6.64 (d, J(14, 13) =
3.7 Hz, 1H, H-14); 6.67 (d, J(13, 14) = 3.7 Hz, 1H, H-13). 13C-NMR (CDCl3) (ppm) δ: 77.50 (d, C-1);
72.35 (d, C-3); 49.34 (t, C-4); 69.34 (s, C-5); 51.31 (d, C-6); 22.40 (t, C-7); 34.32 (t, C-8); 31.19 (d, C-9);
41.03 (t, C-10); 135.70 (s, C-11); 139.15 (s, C-12); 114.76 (d, C-13); 121.00 (d, C-14); 22.81 (q, C-15); 20.81
(q, C-16); 153.39 (s, C-17); 115.21 (q, C-18). HR MS: 377.1265 (M+, C17H22NO3F3S+; calc. 377.1267).
[α]29.1D = −27.1 (c 0.48, EtOH).
2,2,2-Trifluoro-N-(5-((2R,4S,4aR,7R,8aR)-4-hydroxy-4,7-dimethyloctahydro-2H-chromen-2-yl)thiophen-2-
yl)acetamide, (4S)-11. The reaction of amine (4S)-9 (0.052 g) and trifluoroacetic anhydride (0.039 g) in
the presence of 4-DMAP (0.001 g) for 2 h resulted in the yield of (4S)-11 (0.055 g, 80%). 1H-NMR
(CDCl3) (ppm) δ: 0.80-0.88 (m, 1H, Ha-8); 0.82 (d, J(16, 9a) = 6.5 Hz, 3H, H-16); 0.94 (ddd, J(10a, 10e) =
J(10a, 9a) = 12.1 Hz, J(10a, 1a) = 11.2 Hz, 1H, Ha-10); 1.03–1.12 (m, 2H, Ha-6, Ha-7); 1.14 (s, 3H, H-15);
1.33–1.43 (m, 1H, Ha-9); 1.63 (dd, J(4a, 4e) = 13.4 Hz, J(4a, 3a) = 11.6 Hz, 1H, Ha-4); 1.70–1.89 (m, 4H,
He-7, He-8, He-4, He-10); 3.55 (ddd, J(1a, 10a) = 11.2 Hz, J(1a, 6a) = 9.7 Hz, J(1a, 10e) = 4.2 Hz, 1H,
Ha-1); 4.95 (ddd, J(3a, 4a) = 11.6 Hz, J(3a, 4e) = 2.4 Hz, J(3a, 14) = 1.0 Hz, 1H, Ha-3); 6.69 (d, J(14, 13) =
3.7 Hz, 1H, H-14); 6.73 (d, J(13, 14) = 3.7 Hz, 1H, H-13). 13C-NMR (CDCl3) (ppm) δ: 75.80 (d, C-1);
70.71 (d, C-3); 47.54 (t, C-4); 69.34 (s, C-5); 49.31 (d, C-6); 22.40 (t, C-7); 34.32 (t, C-8); 31.19 (d, C-9);
41.03 (t, C-10); 134.84 (s, C-11); 140.70 (s, C-12); 115.76 (d, C-13); 121.00 (d, C-14); 22.41 (q, C-15); 20.81
(q, C-16); 153.39 (s, C-17); 115.32 (q, C-18). HR MS: 377.1265 (M+, C17H22NO3F3S+; calc. 377.1267).
General Procedure for the Preparation of Compounds 12–13. To a solution of amine 9 (1.0 mmol) in
EtOAc, acid chloride (1.0 mmol) in the presence of NEt3 (1 mmol) was added dropwise and the mixture
was stirred at r.t. for 2 h. After the completion of the reaction, 10 mL of a saturated aq. NaHCO3
solution was added to the reaction mixture and extracted with ethyl acetate (3 × 10 mL). The organic
layer was washed with brine (2 × 10 mL) and dried over anhydrous sodium sulphate. The organic
layer was concentrated in a rotary evaporator and separated using an SiO2 column.
N-(5-((2R,4R,4aR,7R,8aR)-4-Hydroxy-4,7-dimethyloctahydro-2H-chromen-2-yl)thiophen-2-yl)benzamide,
(4R)-12. The reaction of amine (4R)-9 (0.130 g) and benzoyl chloride (0.064 g) in the presence of NEt3
(0.046 g) for 2 h resulted in the yield of (4R)-12 (0.056 g, 30%). 1H-NMR (CDCl3) (ppm) δ: 0.88–0.97
(m, 1H, Ha-8); 0.92 (d, J(16, 9a) = 6.5 Hz, 3H, H-16); 1.05 (ddd, J(10a, 10e) = J(10a, 9a) = 12.1 Hz, J(10a,
1a) = 11.2 Hz, 1H, Ha-10); 1.09–1.20 (m, 2H, Ha-6, Ha-7); 1.24 (s, 3H, H-15); 1.41–1.52 (m, 1H, Ha-9);
1.67 (dd, J(4a, 4e) = 13.4 Hz, J(4a, 3a) = 11.6 Hz, 1H, Ha-4); 1.72 (dm, J(8e, 8a) = 13.1 Hz, other J < 3.5 Hz,
1H, He-8); 1.77–1.83 (m, 1H, He-7); 1.95 (dd, J(4e, 4a) = 13.4 Hz, J(4e, 3a) = 2.4 Hz, 1H, He-4); 1.97 (dm,
J(10e, 10a) = 12.1 Hz, other J < 4.5 Hz, 1H, He-10); 3.26 (ddd, J(1a, 10a) = 11.2 Hz, J(1a, 6a) = 9.7 Hz, J(1a,
10e) = 4.2 Hz, 1H, Ha-1); 4.62 (ddd, J(3a, 4a) = 11.6 Hz, J(3a, 4e) = 2.4 Hz, J(3a, 14) = 1.0 Hz, 1H, Ha-3);
6.60 (dd, J(14, 13) = 4.2 Hz, J(14, 3a) = 1.0 Hz, 1H, H-14); 6.73 (d, J(13, 14) = 4.2 Hz, 1H, H-13); 7.42–7.46
(m, 2H, H-20, H-22); 7.49–7.54 (m, 1H, H-21); 7.82–7.86 (m, 2H, H-19, H-23). 13C-NMR (CDCl3) (ppm)
δ: 77.79 (d, C-1); 72.70 (d, C-3); 49.53 (t, C-4); 70.81 (s, C-5); 41.93 (d, C-6); 22.96 (t, C-7); 34.34 (t, C-8);
31.38 (d, C-9); 41.38 (t, C-10); 133.21 (s, C-11); 138.49 (s, C-12); 111.64 (d, C-13); 120.62 (d, C-14); 30.83
(q, C-15); 22.03 (q, C-16); 163.58 (s, C-17); 137.84 (s, C-18); 127.01 (d, C-19, C-23); 132.10 (d, C-21); 128.86
(d, C-20, C-22). HR MS: 385.1710 (M+, C22H27O3NS+; calc. 385.1706). [α]
28.1
D = +22.38 (c 0.143, EtOH).
N-(5-((2R,4S,4aR,7R,8aR)-4-Hydroxy-4,7-dimethyloctahydro-2H-chromen-2-yl)thiophen-2-yl)benzamide,
(4S)-12. The reaction of amine (4S)-9 (0.040 g) and benzoyl chloride (0.021 g) in the presence of NEt3
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(0.015 g) for 2 h resulted in the yield of (4S)-12 (0.020 g, 40%). 1H-NMR (CDCl3) (ppm) δ: 0.88–0.97
(m, 1H, Ha-8); 0.92 (d, J(16, 9a) = 6.5 Hz, 3H, H-16); 1.05 (ddd, J(10a, 10e) = J(10a, 9a) = 12.1 Hz, J(10a,
1a) = 11.2 Hz, 1H, Ha-10); 1.09–1.20 (m, 2H, Ha-6, Ha-7); 1.24 (s, 3H, H-15); 1.41–1.52 (m, 1H, Ha-9);
1.67 (dd, J(4a, 4e) = 13.4 Hz, J(4a, 3a) = 11.6 Hz, 1H, Ha-4); 1.72 (dm, J(8e, 8a) = 13.1 Hz, other J <
3.5 Hz, 1H, He-8); 1.77–1.83 (m, 1H, He-7); 1.95 (dd, J(4e, 4a) = 13.4 Hz, J(4e, 3a) = 2.4 Hz, 1H, He-4);
1.97 (dm, J(10e, 10a) = 12.1 Hz, other J < 4.5 Hz, 1H, He-10); 3.57 (ddd, J(1a, 10a) = 11.2 Hz, J(1a, 6a) =
9.7 Hz, J(1a,10e) = 4.2 Hz, 1H, Ha-1); 4.96 (ddd, J(3a, 4a) = 11.6 Hz, J(3a, 4e) = 2.4 Hz, J(3a, 14) = 1.0 Hz,
1H, Ha-3); 6.60 (dd, J(14, 13) = 4.2 Hz, J(14, 3a) = 1.0 Hz, 1H, H-14); 6.73 (d, J(13, 14) = 4.2 Hz, 1H,
H-13); 7.42–7.46 (m, 2H, H-20, H-22); 7.49–7.54 (m, 1H, H-21); 7.82–7.86 (m, 2H, H-19, H-23). 13C-NMR
(CDCl3) (ppm) δ: 75.72 (d, C-1); 70.75 (d, C-3); 47.60 (t, C-4); 69.39 (s, C-5); 49.28 (d, C-6); 22.44 (t, C-7);
34.29 (t, C-8); 31.25 (d, C-9); 41.19 (t, C-10); 133.99 (s, C-11); 138.31 (s, C-12); 111.70 (d, C-13); 120.60
(d, C-14); 28.12 (q, C-15); 22.11 (q, C-16); 163.57 (s, C-17); 138.40 (s, C-18); 127.03 (d, C-19, C-23); 131.96
(d, C-21); 128.70 (d, C-20, C-22). HR MS: 385.1710 (M+, C22H27O3NS+; calc. 385.1706). [α]
29.1
D = +4.54
(c 0.22, EtOH).
N-(5-((2R,4R,4aR,7R,8aS)-4-Hydroxy-4,7-dimethyloctahydro-2H-chromen-2-yl)thiophen-2-yl)adamantane-
1-carboxamide, (4R)-13. The reaction of amine (4R)-9 (0.055 g) and 1-adamantanecarbonyl chloride
(0.040 g) in the presence of NEt3 (0.030 g) for 2 h resulted in the yield of (4R)-13 (0.016 g, 20%).
1H-NMR (CDCl3) (ppm) δ: 0.87–0.96 (m, 1H, Ha-8); 0.89 (d, J(16, 9a) = 6.5 Hz, 3H, H-16); 0.98–1.09
(m, 1H, Ha-10); 1.09–1.16 (m, 2H, Ha-6, Ha-7); 1.21 (s, 3H, H-15); 1.40–1.49 (m, 1H, Ha-9); 1.67–1.77
(m, 7H, Ha-4, 2H-21, 2H-23, 2H-27); 1.84–1.97 (m, 2H, He-8, He-7); 1.91 (bs, 6H, 2H-19, 2H-25, 2H-26);
1.98–2.01 (m, 2H, He-4, He-10); 2.06 (bs, 3H, H-20, H-22, H-24); 3.23 (ddd, J(1a, 10a) = 11.2 Hz, J(1a, 6a)
= 9.7 Hz, J(1a, 10e) = 4.2 Hz, 1H, Ha-1); 4.57 (d, J(3a, 4a) = 11.6 Hz, 1H, Ha-3); 6.45 (d, J(14, 13) = 4.2 Hz,
1H, H-14); 6.68 (d, J(13, 14) = 4.2 Hz, 1H, H-13). 13C-NMR (CDCl3) (ppm) δ: 77.37 (d, C-1); 72.48
(d, C-3); 49.50 (t, C-4); 70.71 (s, C-5); 51.89 (d, C-6); 22.91 (t, C-7); 34.23 (t, C-8); 31.34 (d, C-9); 41.31 (t,
C-10); 136.97 (s, C-11); 138.56 (s, C-12); 110.26 (d, C-13); 120.19 (d, C-14); 21.08 (q, C-15); 22.05 (q, C-16);
174.08 (s, C-17); 40.69 (s, C-18); 38.99(t, C-19, C-25, C-26); 27.89 (d, C-20, C-22, C-24); 36.23 (t, C-21, C-23,
C-27). HR MS: 443.2481 (M+, C26H37O3NS+; calc. 443.2489). [α]
27.1
D = +7.9 (c 0.304, EtOH).
N-(5-((2R,4S,4aR,7R,8aS)-4-Hydroxy-4,7-dimethyloctahydro-2H-chromen-2-yl)thiophen-2-yl)adamantane-1-
carboxamide, (4S)-13. The reaction of amine (4S)-9 (0.290 g) and 1-adamantanecarbonyl chloride
(0.297 g) in the presence of NEt3 (0.300 g) for 2 h resulted in the yield of (4S)-13 (0.065 g, 14%). 1H-NMR
(CDCl3) (ppm) δ: 0.87–0.96 (m, 1H, Ha-8); 0.89 (d, J(16, 9a) = 6.5 Hz, 3H, H-16); 1.00 (dd, J(10a, 10e) =
J(10a, 9a) = 12.1 Hz, 1H, Ha-10); 1.09–1.16 (m, 2H, Ha-6, Ha-7); 1.21 (s, 3H, H-15); 1.40–1.49 (m, 1H,
Ha-9); 1.66–1.75 (m, 7H, Ha-4, 2H-21, 2H-23, 2H-27); 1.77–1.89 (m, 2H, He-8, He-7); 1.90 (bs, 6H, 2H-19,
2H-25, 2H-26); 1.92–1.95 (m, 2H, He-4, He-10); 2.05 (bs, 3H, H-20, H-22, H-24); 3.53 (ddd, J(1a, 10a) =
11.2 Hz, J(1a, 6a) = 9.7 Hz, J(1a, 10e) = 4.2 Hz, 1H, Ha-1); 4.91 (dd, J(3a, 4a) = 11.6 Hz, J(3a, 4e) = 2.4 Hz,
1H, Ha-3); 6.44 (d, J(14, 13) = 4.2 Hz, 1H, H-14); 6.67 (d, J(13, 14) = 4.2 Hz, 1H, H-13). 13C-NMR (CDCl3)
(ppm) δ: 75.51 (d, C-1); 70.68 (d, C-3); 47.63 (t, C-4); 69.43 (s, C-5); 49.18 (d, C-6); 22.47 (t, C-7); 34.33
(t, C-8); 31.15 (d, C-9); 41.08 (t, C-10); 137.70 (s, C-11); 138.37 (s, C-12); 110.21 (d, C-13); 120.24 (d, C-14);
28.11 (q, C-15); 22.10 (q, C-16); 174.06 (s, C-17); 40.63 (s, C-18); 39.11(t, C-19, C-25, C-26); 27.86 (d, C-20,
C-22, C-24); 36.25 (t, C-21, C-23, C-27). HR MS: 443.2481 (M+, C26H37O3NS+; calc. 443.2489).[α]
25.0
D =
+19.3 (c 0.114, EtOH).
3.2. Tdp1 Assay
The pET 16B-Tdp1 was kindly provided by Dr. K.W. Caldecott (University of Sussex, United
Kingdom). Recombinant Tdp1 was expressed in Escherichia coli BL21(DE3) and was purified by
chromatography on Ni-chelating resin and phosphocellulose P11, as described in [29].
Real-time Tdp1 activity measurements were carried out as described in [9]. In brief, Tdp1-biosensor
(50 nM) was incubated in a buffer that contains 50 mM Tris-HCl pH 8.0, 50 mM NaCl, and 7 mM
β-mercaptoethanol (200 µL). The mixture was then supplemented with purified Tdp1 (1.3 nM) and various
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concentrations of the inhibitor. Fluorescence measurements (Ex485/Em520 nm) were carried out during the
linear phase of reaction (from 0 to 8 min) every 55 s. The reactions were incubated at a constant temperature
of 26 ◦C using a POLARstar OPTIMA fluorimeter (BMG LABTECH). The influence of the compounds was
evaluated by comparing the fluorescence increase rate in their presence to that of 1.5% DMSO control wells.
The data were imported into the MARS Data Analysis 2.0 program (BMG LABTECH), and IC50 values
were calculated by non-linear curve fitting. Tdp1-biosensor 5′-(5,6 FAM-aac gtc agg gtc ttc c-BHQ1)-3′ was
synthesised in the Laboratory of Biomedical Chemistry, Institute of Chemical Biology and Fundamental
Medicine, Novosibirsk, Russia.
3.3. Binding Studies
Synthetic DNA encoding human Tdp1 (residues 149-608 [2]) was cloned into pET-28a(+)
(GenScript), which was then transformed into Escherichia coli BL21(DE3) for recombinant protein
production. Protein production was induced with 1 mM IPTG at 28 ◦C with overnight incubation.
Tdp1 was purified using affinity and size exclusion chromatography. Fluorescence was measured
using a PerkinElmer EnSpire Multimode Reader. Tdp1 concentration was 10 µM and compound
concentrations were 1 µM, 2.5 µM, 5 µM, 10 µM, 15 µM, 20 µM, 30 µM, 50 µM, 100 µM, 200 µM,
350 µM, 500 µM, and 750 µM. Buffer was 20 mM Tris and 250 mM NaCl (pH 8). Excitation wavelength
was 280 nm and intrinsic fluorescence was measured between 300 and 450 nm. Control experiments
with Tdp1 or compound on its own were also conducted. Background fluorescence arising from the
compounds was subtracted from the final spectrum. The total volume per well was 30 µL. Dissociation
constant (KD) values were calculated using the following formula (1), which takes non-specific binding
into account [32].
I =
Imax × [LT]
KD + [LT]
+ Ns[LT]
I indicates changes in fluorescence intensity from the titrations, Imax indicates the maximum
fluorescence intensity change, [LT] is the titrated ligand concentration, and Ns is the non-specific term.
Non-linear curve fitting was conducted using SigmaPlot 13.0 (Systat Software, San Jose, CA, USA).
Experiments were conducted in triplicate and the errors shown are standard derivations.
3.4. Molecular Modelling Methods
Molecular modelling and the generation of molecular descriptors of Tdp1 inhibitors were
conducted as described in [10]. Briefly, the crystal structure of Tdp1 was used for docking (PDB ID:
1MU7) [33] with the GOLD v5.4 software and the molecular descriptors were generated using QikProp
v5.2 [34,35].
4. Conclusions
In this study, we reported a new class of Tdp1 inhibitors that are based on the (-)-isopulegol-
derived octahydro-2H-chromene scaffold. By using a three-step reaction, a series of chiral heterocyclic
compounds that contain the octahydro-2H-chromene scaffold and different amide substituents
were synthesised. These structural series of compounds were found to be good inhibitors and
binders of Tdp1, with IC50 and KD values in the low micromolar concentration range. In particular,
the octahydro-2H-chromen-4-ol derivative with 1-adamantane moiety (4S)-13 appeared to be the most
potent inhibitor of Tdp1 among this series, with an IC50 value of 1.24 µM. The plausible binding modes
of these compounds to Tdp1 were also predicted, which found that these compounds may block the
access of substrates to the enzyme active site. Overall, our results helped establish a structural-activity
relationship for these novel octahydro-2H-chromene-based Tdp1 inhibitors. This information will be
useful for future inhibitor development work for Tdp1.
Supplementary Materials: The Supplementary Materials are available online.
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